$0.00 EPS Expected for Travelzoo (TZOO); Alnylam Pharmaceuticals Has 0.77 Sentiment

June 26, 2017 - By Vivian Park

Analysts expect Travelzoo (NASDAQ:TZOO) to report $0.00 EPS on July, 27. About 6,899 shares traded. Travelzoo (NASDAQ:TZOO) has risen 32.03% since June 26, 2016 and is uptrending. It has outperformed by 15.33% the S&P500.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $7.54 billion. The Firm is engaged in the discovery, development and commercialization of ribonucleic acid interference (RNAi) therapeutics. It currently has negative earnings. The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Since May 25, 2017, it had 0 buys, and 8 selling transactions for $3.93 million activity. $21,500 worth of Travelzoo (NASDAQ:TZOO) shares were sold by BARTEL RALPH. $651,988 worth of Travelzoo (NASDAQ:TZOO) was sold by AZZURRO CAPITAL INC. Ralph Bartel 2005 Trust also sold $651,988 worth of Travelzoo (NASDAQ:TZOO) on Thursday, May 25.

Travelzoo, formerly Travelzoo Inc., is a media commerce company. The company has market cap of $143.13 million. The Firm informs over 28 million members in Asia Pacific, Europe and North America, as well as various Website users, about the travel and entertainment deals available from a range of companies. It has a 27.15 P/E ratio. The Firm operates through three divisions: Asia Pacific, Europe and North America.

Investors sentiment increased to 1.45 in Q4 2016. Its up 0.52, from 0.93 in 2016Q3. It increased, as 5 investors sold Travelzoo shares while 15 reduced holdings. 10 funds opened positions while 19 raised stakes. 3.39 million shares or 1.63% more from 3.33 million shares in 2016Q3 were reported. California Pub Employees Retirement Systems holds 0% of its portfolio in Travelzoo (NASDAQ:TZOO) for 136,000 shares. Jpmorgan Chase And holds 0% or 5,058 shares in its portfolio. 3,823 were reported by Deutsche Bankshares Ag. Millennium Limited Liability Corp holds 0% in Travelzoo (NASDAQ:TZOO) or 37,513 shares. Goldman Sachs Group holds 0% or 41,757 shares. Moreover, Manufacturers Life The has 0% invested in Travelzoo (NASDAQ:TZOO). Blackrock Investment Limited reported 1,076 shares. Renaissance Limited Liability reported 474,100 shares or 0.01% of all its holdings. Bancorporation Of America Corp De invested in 102 shares or 0% of the stock. Tower Rech Cap Lc (Trc) reported 2,119 shares or 0% of all its holdings. D E Shaw & holds 0% or 70,441 shares in its portfolio. Blackrock Fund Advsrs has 19,919 shares for 0% of their portfolio. Northern Trust has invested 0% in Travelzoo (NASDAQ:TZOO). Jacobs Levy Equity has 12,800 shares. California-based Blackrock Institutional Tru Communications Na has invested 0% in Travelzoo (NASDAQ:TZOO).

12 West Capital Management Lp holds 4.66% of its portfolio in Alnylam Pharmaceuticals, Inc. for 700,000 shares. Granite Point Capital Management L.P. owns 110,000 shares or 3.28% of their US portfolio. Moreover, Fic Capital Inc has 3.25% invested in the company for 172,242 shares. The New York-based Opus Point Partners Management Llc has invested 2.65% in the stock. Slate Path Capital Lp, a New York-based fund reported 2.00 million shares.

Since January 1, 0001, it had 2 insider purchases, and 6 selling transactions for $15.68 million activity.

Ratings analysis reveals 57% of Alnylam Pharma’s analysts are positive. Out of 7 Wall Street analysts rating Alnylam Pharma, 4 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $36.0 while the high is $137.0. The stock’s average target of $87.50 is 7.68% above today’s ($81.26) share price. ALNY was included in 7 notes of analysts from October 6, 2016. The stock has “Mkt Perform” rating by Leerink Swann on Thursday, October 6. FBR Capital maintained it with “Outperform” rating and $100.0 target in Thursday, October 6 report. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Thursday, October 6 by Needham. The firm has “Hold” rating by Stifel Nicolaus given on Thursday, October 6. JP Morgan downgraded the shares of ALNY in report on Thursday, October 6 to “Neutral” rating. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Ladenburg Thalmann on Thursday, February 2. Chardan Capital Markets maintained it with “Buy” rating and $77.0 target in Thursday, October 6 report.